Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (stock code: 09989) reported its monthly return for the period ended 31 January 2026. The total authorised and registered share capital remained at RMB 1,467,296,204. This consists of 220,094,500 H shares (RMB 1 par value) and 1,247,201,704 A shares (RMB 1 par value), with no changes from the previous month.

The issued H share capital stood at 220,094,500 shares, while the issued A share capital totaled 1,247,201,704 shares, both unchanged. The company confirmed compliance with the public float requirements for H shares, noting that 5% of the total number of issued H shares (excluding treasury shares) is the applicable threshold.